Hibsago (bepirovirsen) approved in the US for the treatment of chronic hepatitis B (CHB)
Approval based on phase III data showing unprecedented functional cure rates compared to standard of care
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


